Amin Safa1,2, Abolfazl Bagherifard3, Hamadalla Hadi Al-Baseesee4, Azade Amini Kadijani5, Hooman Yahyazadeh3, Masoumeh Azizi6, Abolfazl Akbari7, Alireza Mirzaei3. 1. Institute of Research and Development, Duy Tan University, Da Nang, Viet Nam. 2. Department of Immunology, Ophthalmology and ENT, School of Medicine, Complutense University, Madrid, Spain. 3. Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran. 4. College of Medicine, University of Al-Kufa, Kufa, Najaf, Iraq. 5. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. 7. Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract
OBJECTIVE: The identification of early-stage osteoarthritis (OA) is crucial for the deceleration of its progression; however, no reliable biomarker is available for this purpose. The current study aimed to determine the role of serum calprotectin in the detection of early-stage knee OA. DESIGN: In a case-control study, serum samples were collected from 84 patients with primary bilateral knee OA and 52 healthy controls. The radiographic grading of knee OA was performed using the Kellgren-Lawrence classification system. Serum concentrations of calprotectin were measured using an enzyme-linked immunosorbent assay. RESULTS: The mean serum calprotectin level was 2908 ± 2516 ng/mL in OA patients and 901 ± 875 ng/mL in healthy control subjects (P < 0.001). Mean serum calprotectin levels were significantly higher in the lower stages of OA: 3740 ± 2728 ng/mL in OA grade I, 3100 ± 2084 ng/mL in OA grade II, 2246 ± 1418 ng/mL in OA grade III, and 2035 ± 765 ng/mL in OA grade IV (P = 0.047). Serum calprotectin levels were significantly higher in patients with a disease duration <42 months compared with those with a disease duration >42 months (P = 0.043). CONCLUSION: Serum calprotectin level increases significantly in the early stages of OA and shows a reverse association with disease severity. Therefore, it could be suggested as a promising blood-based marker for early-stage knee OA.
OBJECTIVE: The identification of early-stage osteoarthritis (OA) is crucial for the deceleration of its progression; however, no reliable biomarker is available for this purpose. The current study aimed to determine the role of serum calprotectin in the detection of early-stage knee OA. DESIGN: In a case-control study, serum samples were collected from 84 patients with primary bilateral knee OA and 52 healthy controls. The radiographic grading of knee OA was performed using the Kellgren-Lawrence classification system. Serum concentrations of calprotectin were measured using an enzyme-linked immunosorbent assay. RESULTS: The mean serum calprotectin level was 2908 ± 2516 ng/mL in OA patients and 901 ± 875 ng/mL in healthy control subjects (P < 0.001). Mean serum calprotectin levels were significantly higher in the lower stages of OA: 3740 ± 2728 ng/mL in OA grade I, 3100 ± 2084 ng/mL in OA grade II, 2246 ± 1418 ng/mL in OA grade III, and 2035 ± 765 ng/mL in OA grade IV (P = 0.047). Serum calprotectin levels were significantly higher in patients with a disease duration <42 months compared with those with a disease duration >42 months (P = 0.043). CONCLUSION: Serum calprotectin level increases significantly in the early stages of OA and shows a reverse association with disease severity. Therefore, it could be suggested as a promising blood-based marker for early-stage knee OA.
Entities:
Keywords:
biomarker; early stage; knee; osteoarthritis
Authors: Leif Ryd; Mats Brittberg; Karl Eriksson; Jukka S Jurvelin; Anders Lindahl; Stefan Marlovits; Per Möller; James B Richardson; Matthias Steinwachs; Marcy Zenobi-Wong Journal: Cartilage Date: 2015-07 Impact factor: 4.634
Authors: Hala Zreiqat; Daniele Belluoccio; Margaret M Smith; Richard Wilson; Lynn A Rowley; Katie Jones; Yogambha Ramaswamy; Thomas Vogl; Johannes Roth; John F Bateman; Christopher B Little Journal: Arthritis Res Ther Date: 2010-01-27 Impact factor: 5.156
Authors: M Lotz; J Martel-Pelletier; C Christiansen; M-L Brandi; O Bruyère; R Chapurlat; J Collette; C Cooper; G Giacovelli; J A Kanis; M A Karsdal; V Kraus; W F Lems; I Meulenbelt; J-P Pelletier; J-P Raynauld; S Reiter-Niesert; R Rizzoli; L J Sandell; W E Van Spil; J-Y Reginster Journal: Ann Rheum Dis Date: 2013-07-29 Impact factor: 19.103